Payment overview · 2025
General Payments
$333.58
12 reported records · 5 companies
Healthcare provider profile · identity verified
Jayesh Madrecha, DO
Allopathic & Osteopathic Physicians|General Practice · KENNER, LA · NPI 1831502020
Verified facts
What the public records show
CMS Open Payments records show Jayesh Madrecha, DO received $333.58 in general payments during 2025 across 12 reported records.
Gilead Sciences, Inc. accounted for 66.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Descovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $222.86 | 66.8% | 6 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $37.92 | 11.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.31 | 10.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.48 | 7.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.01 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $333.58 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $132.66 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $37.92 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 694 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 70 |
| Losartan Potassium | Losartan Potassium | 214 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 67 |
| Gabapentin | Gabapentin | 192 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 69 |
| Metformin Hcl | Metformin Hcl | 122 | 39 |
| Lisinopril | Lisinopril | 121 | 40 |
| Omeprazole | Omeprazole | 121 | 38 |
| Ezetimibe | Ezetimibe | 119 | 45 |
| Glimepiride | Glimepiride | 119 | 36 |
| Azelastine Hcl | Azelastine Hcl | 109 | 49 |
| Allopurinol | Allopurinol | 102 | 33 |
| Trazodone Hcl | Trazodone Hcl | 93 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 92 | 36 |
| Metformin Hcl Er | Metformin Hcl | 91 | 34 |
| Valsartan | Valsartan | 91 | 28 |
| Sertraline Hcl | Sertraline Hcl | 89 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 28 |
| Carvedilol | Carvedilol | 81 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 28 |
| Furosemide | Furosemide | 75 | 33 |
| Ozempic | Semaglutide | 73 | 23 |
| Simvastatin | Simvastatin | 73 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 27 |
| Jardiance | Empagliflozin | 69 | 26 |
| Meloxicam | Meloxicam | 69 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 36 |
| Mounjaro | Tirzepatide | 61 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 19 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 56 | 16 |
| Pregabalin | Pregabalin | 53 | 14 |
| Finasteride | Finasteride | 47 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 16 |
| Eliquis | Apixaban | 46 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 16 |
| Potassium Chloride | Potassium Chloride | 43 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | 15 |
| Nifedipine Er | Nifedipine | 40 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | 16 |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 13 |
| Ketoconazole | Ketoconazole | 36 | 14 |
| Spironolactone | Spironolactone | 36 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 11 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 11 |
| Celecoxib | Celecoxib | 34 | 13 |
| Montelukast Sodium | Montelukast Sodium | 34 | 13 |
| Fluconazole | Fluconazole | 33 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | 12 |
| Prednisone | Prednisone | 28 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 25 |
| Famotidine | Famotidine | 27 | 11 |
| Baclofen | Baclofen | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | 14 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Colchicine | Colchicine | 21 | 11 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Mupirocin | Mupirocin | 20 | 15 |
| Nexium | Esomeprazole Magnesium | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 14 |
| Cephalexin | Cephalexin | 17 | 14 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $333.58 · 12 records | Gilead Sciences, Inc. | ABRYSVO, COMIRNATY, FARXIGA, NEXLETOL, NEXPLANON, PREVNAR 20, Yeztugo | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error